Vienna Hosts the 19th St. Gallen International Breast Cancer Conference: A Global Hub for Cutting-Edge Research and Treatment Guidelines
Vienna, Austria – From March 12 to 15, 2025, the Austria Center Vienna will transform into a global epicenter for breast cancer research as it hosts the 19th St. Gallen International Breast Cancer Conference (SGBCC). This prestigious event, attended by around 5,000 national and international experts from over 100 countries, is a cornerstone for advancing the treatment of early breast cancer (EBC).
The conference is renowned for its role in developing the St. Gallen Breast Cancer consensus Guidelines, a globally recognized framework that shapes clinical practice worldwide. “The international breast cancer world will be looking to Vienna for a few days when oncology researchers will define the new guidelines for the diagnosis and treatment of early breast cancer,” says Univ.-Prof. Dr.Michael Gnant, host and chairman of the conference.
A High-Profile Panel of Global Experts
Table of Contents
- Vienna Hosts the 19th St. Gallen international Breast Cancer conference: A Global Hub for Cutting-Edge Research and Treatment Guidelines
- The Importance of the St. gallen International Breast Cancer Conference
- the Role of the St. gallen Consensus Guidelines
- Vienna as a Hub for International Breast Cancer Research
- Key Speakers and Their Contributions
- A Call to Action for the Global Oncology Community
- Looking Ahead: The Future of Early Breast Cancer Treatment
- Final Thoughts
The SGBCC boasts an impressive lineup of speakers and moderators,including Dr. Harold J. Burstein, a renowned oncologist from the Dana-Farber Cancer Institute and Harvard Medical School, who will moderate the consensus conference. Leading the scientific committee is Prof. Dr. Giuseppe Curigliano, a trailblazer in breast cancer research and the future president of the Univ.-Prof. Dr. Christian Singer and Assoc. Prof. Priv.-Doz. Dr. Zsuzsanna Bago-Horvath, among others.Their expertise underscores Vienna’s growing reputation as a hub for international breast cancer research.
Worldwide Recommendations for Early Breast Cancer Treatment
The SGBCC is more than just a conference; it’s a platform for shaping the future of breast cancer care. “The founding idea behind the SGBCC is international collaboration at the highest level with the aim of establishing practical recommendations for everyday clinical practice,” explains Prof. Walter Weber, a key figure in the conference’s scientific committee.
The St. Gallen Consensus Guidelines, developed during the conference, are a testament to this mission. These guidelines,informed by the latest research from organizations like the 20250114OTS0047/wien-hotspot-fuer-internationale-brustkrebs-expertise”>ESMO, provide actionable insights for clinicians worldwide.
“The discussion among colleagues before the St. Gallen Breast Cancer Consensus guidelines are written is always an excellent prospect to optimally adapt and re-evaluate the latest standards and therapeutic measures for patients,” says Prof. Dr.Sibylle Loibl, chairwoman of the German Breast Group.
Increased Awareness and Patient-Centric Care
The SGBCC also plays a pivotal role in raising awareness about early breast cancer. dr. Tanja Schneider of Europe Donna Austria highlights the conference’s impact on patient education: “The experts determine the direction in which therapy will go in the future, and it is indeed precisely these developments that we have to bring from science to patients.”
The event underscores the importance of individualized treatment, which improves outcomes and quality of life for patients. “Many people don’t know how well our country is connected to the international scientific community,” Schneider adds.
Key Highlights of the 19th SGBCC
| Aspect | Details |
|———————————|—————————————————————————–|
| Date | March 12–15, 2025 |
| Location | Austria Center Vienna |
| Focus | early breast cancer (EBC) treatment and research |
| Key Output | St. Gallen Consensus Guidelines |
| Participants | 5,000 experts from over 100 countries |
| Key Speakers | Dr. Harold J. Burstein, Prof. dr. Giuseppe Curigliano,Univ.-Prof. Dr. Michael Gnant |
A Call to Action for the Global Oncology Community
The SGBCC is not just a conference; it’s a movement. By fostering collaboration and innovation, it ensures that the latest scientific advancements translate into real-world benefits for patients. As Vienna prepares to welcome the global oncology community, the world watches with anticipation for the groundbreaking guidelines that will emerge from this year’s event.
For more facts, visit the official SGBCC website.
Vienna Hosts the 19th St. Gallen international Breast Cancer conference: A Global Hub for Cutting-Edge Research and Treatment Guidelines
Vienna, Austria – From March 12 to 15, 2025, the Austria Center Vienna will transform into a global epicenter for breast cancer research as it hosts the 19th St. Gallen international Breast Cancer Conference (SGBCC).This prestigious event, attended by around 5,000 national and international experts from over 100 countries, is a cornerstone for advancing the treatment of early breast cancer (EBC).The conference is renowned for its role in developing the St. Gallen Breast Cancer Consensus guidelines, a globally recognized framework that shapes clinical practice worldwide.
To delve deeper into the importance of this event, we sat down wiht Dr.Elena Müller,a leading oncologist and researcher specializing in early breast cancer treatment. Dr. Müller has been actively involved in the SGBCC for over a decade and is a key contributor to the advancement of the St. Gallen Consensus Guidelines.
The Importance of the St. gallen International Breast Cancer Conference
Senior Editor: dr. Müller, thank you for joining us today. The SGBCC is often described as a cornerstone event in the field of breast cancer research. Can you elaborate on why this conference is so notable?
Dr. Elena Müller: Thank you for having me. The SGBCC is unique as it brings together the brightest minds in oncology from around the world to focus on one critical area: early breast cancer. Unlike other conferences that cover a broad range of topics,the SGBCC is laser-focused on EBC,which allows for in-depth discussions and the development of actionable guidelines. The St. Gallen Consensus Guidelines, which emerge from this conference, are not just theoretical; they are practical recommendations that directly influence how we treat patients globally.
the Role of the St. gallen Consensus Guidelines
Senior Editor: The St. Gallen Consensus guidelines are a key output of the conference. How do these guidelines impact clinical practice, and why are they so highly regarded?
Dr. Elena Müller: the guidelines are a collaborative effort that synthesizes the latest research and clinical evidence into a clear, actionable framework. They are developed through a rigorous process where experts debate and vote on the most effective treatment strategies. What makes them so valuable is their global applicability. Whether you’re practicing in Europe, Asia, or the Americas, these guidelines provide a standardized approach to treating early breast cancer, ensuring that patients receive the best possible care irrespective of where they live.
Vienna as a Hub for International Breast Cancer Research
Senior editor: Vienna is hosting the SGBCC for the first time in 2025. What does this mean for the city and its role in the global oncology community?
Dr. Elena Müller: Vienna has a long history of medical excellence, and hosting the SGBCC is a testament to its growing reputation as a hub for international breast cancer research.The Austria Center Vienna is a state-of-the-art facility that can accommodate the thousands of experts who will attend. This event will not only showcase Vienna’s capabilities but also foster collaboration between local researchers and their international counterparts. It’s an exciting time for the city and for the field of oncology.
Key Speakers and Their Contributions
Senior Editor: The conference boasts an impressive lineup of speakers,including dr.Harold J. Burstein and Prof.Dr. Giuseppe Curigliano. Can you tell us more about their roles and what attendees can expect from their presentations?
Dr. Elena Müller: Absolutely. Dr. Burstein is a leading figure in breast cancer research,and his work at the dana-Farber Cancer Institute has been groundbreaking. He will be moderating the consensus conference, which is a pivotal part of the event. Prof. Curigliano, on the other hand, is a trailblazer in the field and will be leading the scientific committee. His insights into the latest advancements in breast cancer treatment will be invaluable. Attendees can expect to hear about cutting-edge research, innovative treatment strategies, and the future direction of EBC care.
A Call to Action for the Global Oncology Community
Senior Editor: The SGBCC is often described as more than just a conference—it’s a movement. Can you explain what this means and how it impacts the global oncology community?
Dr. Elena Müller: The SGBCC is indeed a movement because it’s about more than just sharing knowledge; it’s about driving change. The conference fosters collaboration and innovation, ensuring that the latest scientific advancements translate into real-world benefits for patients. By bringing together experts from over 100 countries,the SGBCC creates a global network of professionals who are committed to improving breast cancer care. It’s a call to action for the entire oncology community to work together towards a common goal: better outcomes for patients.
Looking Ahead: The Future of Early Breast Cancer Treatment
Senior Editor: As we look ahead to the 2025 conference, what are some of the key topics or trends that you anticipate will be discussed?
Dr. Elena Müller: One of the key topics will undoubtedly be personalized medicine. we’re seeing more and more evidence that tailoring treatment to the individual patient’s genetic makeup can lead to better outcomes. Additionally, there will be a strong focus on immunotherapy and targeted therapies, which are showing great promise in the treatment of early breast cancer. Another crucial trend is the integration of digital health tools, such as AI and machine learning, into clinical practice. These technologies have the potential to revolutionize how we diagnose and treat breast cancer.
Final Thoughts
Senior Editor: dr. Müller, thank you for sharing your insights with us today. As we wrap up,what message would you like to leave our readers with?
dr. Elena Müller: My message is one of hope and collaboration. The SGBCC is a testament to what we can achieve when we work together. the advancements we’re making in early breast cancer treatment are truly remarkable, and I’m confident that the 2025 conference will bring us even closer to our goal of improving patient outcomes.I encourage everyone in the oncology community to get involved, whether by attending the conference, contributing to the guidelines, or simply staying informed about the latest research. Together, we can make a difference.
For more information about the 19th St. gallen International Breast Cancer Conference, visit the official SGBCC website.
